PMID- 20032434
OWN - NLM
STAT- MEDLINE
DCOM- 20100126
LR  - 20161125
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 29
IP  - 11
DP  - 2009 Nov
TI  - Radioimmunotherapy of heavily pre-treated, non-Hodgkin's lymphoma patients: 
      efficacy and safety in a routine setting.
PG  - 4771-7
AB  - The aim of the present study waw to assess efficacy and safety of 
      radio-immunotherapy with Zevalin (RIT-Z) in heavily pre-treated, 
      rituximab-refractory patients. PATIENTS AND METHODS: We studied 12 patients with 
      indolent lymphoma and 7 with aggressive lymphoma. The median number of prior 
      rituximab-containing treatments was 2; overall, 3 therapies had been previously 
      given. Ten patients received RIT-Z as salvage therapy, 9 at high risk of relapse 
      received RIT-Z as consolidation. Staging and follow-up were obtained by 
      positron-emission tomography. Outcomes assessed were failure-free survival (FFS) 
      and time to next treatment (TTNT). RESULTS: Overall FFS and TTNT were 5 and 11 
      months, respectively; median follow-up 13 months. Major findings were i) no 
      long-term remissions observed in 7 patients who had not responded to their most 
      recent therapy and ii) lack of association between any pre-therapy variables 
      analysed and outcomes. Different subgroups showed no difference in terms of 
      toxicity. CONCLUSION: We encourage the use of RIT-Z as a consolidation for 
      pre-treated patients with both indolent and aggressive lymphoma.
FAU - Cicone, Francesco
AU  - Cicone F
AD  - Department of Nuclear Medicine, University La Sapienza, Rome, Italy. 
      f.cicone@iol.it
FAU - Baldini, Rossella
AU  - Baldini R
FAU - Cox, Maria Christina
AU  - Cox MC
FAU - Russo, Eleonora
AU  - Russo E
FAU - Torelli, Fabio
AU  - Torelli F
FAU - Tofani, Anna
AU  - Tofani A
FAU - Scopinaro, Francesco
AU  - Scopinaro F
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Murine-Derived)
RN  - 0 (Yttrium Radioisotopes)
RN  - 4F4X42SYQ6 (Rituximab)
RN  - 4Q52C550XK (ibritumomab tiuxetan)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antibodies, Monoclonal/*administration & dosage
MH  - Antibodies, Monoclonal, Murine-Derived
MH  - Drug Resistance, Neoplasm
MH  - Female
MH  - Humans
MH  - Lymphoma, Follicular/*radiotherapy
MH  - Lymphoma, Large B-Cell, Diffuse/*radiotherapy
MH  - Male
MH  - Middle Aged
MH  - Radioimmunotherapy/adverse effects/*methods
MH  - Retrospective Studies
MH  - Rituximab
MH  - Yttrium Radioisotopes/*administration & dosage
EDAT- 2009/12/25 06:00
MHDA- 2010/01/27 06:00
CRDT- 2009/12/25 06:00
PHST- 2009/12/25 06:00 [entrez]
PHST- 2009/12/25 06:00 [pubmed]
PHST- 2010/01/27 06:00 [medline]
AID - 29/11/4771 [pii]
PST - ppublish
SO  - Anticancer Res. 2009 Nov;29(11):4771-7.